Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers

Abstract A new wave of dual Topo I/II inhibitors was designed and synthesised via the hybridisation of spirooxindoles and pyrimidines. In situ selenium nanoparticles (SeNPs) for some derivatives were synthesised. The targets and the SeNP derivatives were examined for their cytotoxicity towards five cancer cell lines. The inhibitory potencies of the best members against Topo I and Topo II were also assayed besides their DNA intercalation abilities. Compound 7d NPs exhibited the best inhibition against Topo I and Topo II enzymes with IC50 of 0.042 and 1.172 μM, respectively. The ability of compound 7d NPs to arrest the cell cycle and induce apoptosis was investigated. It arrested the cell cycle in the A549 cell at the S phase and prompted apoptosis by 41.02% vs. 23.81% in the control. In silico studies were then performed to study the possible binding interactions between the designed members and the target proteins. Graphical Abstract Highlights A new wave of dual Topo I/II inhibitors was designed and synthesised via the hybridisation of spirooxindoles and pyrimidines. In situ selenium nanoparticles (SeNPs) for some derivatives were synthesised. Cytotoxicity, Topo I and Topo II inhibitory assays, and DNA intercalation abilities were evaluated. Compound 7d NPs showed the best Topo I and Topo II inhibition. Cell cycle arrest, apoptosis induction, and molecular docking studies were performed.

[1]  A. Mourad,et al.  Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2′,3′:4,5]thiazolo[3,2-a]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity , 2023, Journal of enzyme inhibition and medicinal chemistry.

[2]  Ali Khalil Ali,et al.  Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies , 2023, RSC advances.

[3]  M. Ghorab,et al.  Synthesis, DFT calculations, and anti-proliferative evaluation of pyrimidine and selenadiazolopyrimidine derivatives as dual Topoisomerase II and HSP90 inhibitors , 2023, Journal of enzyme inhibition and medicinal chemistry.

[4]  Hany E. A. Ahmed,et al.  A novel class of phenylpyrazolone-sulphonamides rigid synthetic anticancer molecules selectively inhibit the isoform IX of carbonic anhydrases guided by molecular docking and orbital analyses , 2023, Journal of biomolecular structure & dynamics.

[5]  A. Al-Taweel,et al.  Cholinesterase Inhibitors from an Endophytic Fungus Aspergillus niveus Fv-er401: Metabolomics, Isolation and Molecular Docking , 2023, Molecules.

[6]  X. Qiao,et al.  Design, synthesis and biological evaluation of dual Topo II/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs. , 2023, European journal of medicinal chemistry.

[7]  C. Supuran,et al.  4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments. , 2023, European journal of medicinal chemistry.

[8]  Faten Farouk,et al.  Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies , 2023, Journal of enzyme inhibition and medicinal chemistry.

[9]  S. Antar,et al.  Ligand-Based Design on the Dog-Bone-Shaped BIBR1532 Pharmacophoric Features and Synthesis of Novel Analogues as Promising Telomerase Inhibitors with In Vitro and In Vivo Evaluations. , 2022, Journal of medicinal chemistry.

[10]  A. Belal,et al.  Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management , 2022, Molecules.

[11]  S. Sushanth Kumar,et al.  Exploration of the Detailed Structure–Activity Relationships of Isatin and Their Isomers As Monoamine Oxidase Inhibitors , 2022, ACS omega.

[12]  Ehab S. Taher,et al.  Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline–Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors , 2022, Pharmaceuticals.

[13]  Kashif Haider,et al.  A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents , 2022, European Journal of Medicinal Chemistry Reports.

[14]  Liao Dong,et al.  Nickel supported on magnetic biochar as a highly efficient and recyclable heterogeneous catalyst for the one‐pot synthesis of spirooxindole‐dihydropyridines , 2022, Applied Organometallic Chemistry.

[15]  F. Agili,et al.  Synthesis, Molecular Docking and Anticancer Activity of Some 5‐Aryl‐5,10‐dihydropyrido[2,3‐ d :6,5‐ d′ ]dipyrimidine‐2,4,6,8‐tetraone Derivatives and Pyrido[2,3‐ d ]pyrimidines , 2022, ChemistrySelect.

[16]  Mohamed S. Nafie,et al.  Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies , 2021, Journal of enzyme inhibition and medicinal chemistry.

[17]  F. Agili,et al.  Novel Uracil Derivatives Depicted Potential Anticancer Agents: In Vitro, Molecular Docking, and ADME Study , 2021, Arabian Journal of Chemistry.

[18]  I. Shurygina,et al.  Selenium Nanoparticles , 2021, Nanotechnology in Medicine.

[19]  A. El-Sayed,et al.  Synthesis, In Silico Prediction and In Vitro Evaluation of Antimicrobial Activity, DFT Calculation and Theoretical Investigation of Novel Xanthines and Uracil Containing Imidazolone Derivatives , 2021, International journal of molecular sciences.

[20]  Chao Ma,et al.  Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma: In Silico, In Vitro, and SAR Studies , 2021, Frontiers in Chemistry.

[21]  Shailee V. Tiwari,et al.  Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions. , 2021, Bioorganic chemistry.

[22]  H. Santos,et al.  Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics , 2021, Advanced healthcare materials.

[23]  M. Tajbakhsh,et al.  Synthesis, in silico, in vitro and in vivo evaluations of isatin aroylhydrazones as highly potent anticonvulsant agents. , 2021, Bioorganic chemistry.

[24]  Girinath G. Pillai,et al.  In-silico driven design and development of spirobenzimidazo-quinazolines as potential DNA gyrase inhibitors. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  M. Elsohly,et al.  Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors. , 2020, Bioorganic & medicinal chemistry.

[26]  F. Agili,et al.  Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives , 2020, Molecules.

[27]  M. Elsohly,et al.  Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. , 2020, Bioorganic chemistry.

[28]  M. Elsohly,et al.  Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. , 2020, Bioorganic chemistry.

[29]  Asmaa M. AboulMagd,et al.  New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study. , 2020, Bioorganic chemistry.

[30]  R. Baharfar,et al.  Design and characterization of Fe 3 O 4 /GO/Au‐Ag nanocomposite as an efficient catalyst for the green synthesis of spirooxindole‐dihydropyridines , 2020 .

[31]  T. Daveedu,et al.  One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies. , 2020, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[32]  L. Legnani,et al.  Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents. , 2020, Current medicinal chemistry.

[33]  S. El-Metwally,et al.  Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II. , 2019, Bioorganic chemistry.

[34]  L. Armstrong,et al.  Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations , 2019, Molecular Pharmacology.

[35]  Varun,et al.  Isatin and its derivatives: a survey of recent syntheses, reactions, and applications. , 2019, MedChemComm.

[36]  L. Rashed,et al.  Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies , 2018, Journal of enzyme inhibition and medicinal chemistry.

[37]  Herman Yeger,et al.  Combination therapy in combating cancer , 2017, Oncotarget.

[38]  Shuguang Yuan,et al.  Using PyMOL as a platform for computational drug design , 2017 .

[39]  A. Khalil,et al.  Novel nanofibrillated cellulose/polyvinylpyrrolidone/silver nanoparticles films with electrical conductivity properties. , 2017, Carbohydrate polymers.

[40]  K. Kohli,et al.  Green Synthesis of Selenium Nanoparticles from Broccoli, Characterization, Application and Toxicity , 2017 .

[41]  Anil H. Gore,et al.  Synthesis, biological evaluation and molecular docking studies of some novel indenospiro derivatives as anticancer agents , 2016 .

[42]  J. Ilaš,et al.  Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. , 2016, Journal of medicinal chemistry.

[43]  Wenfeng Liu,et al.  Discovery of 7‐Methyl‐10‐Hydroxyhomocamptothecins with 1,2,3‐Triazole Moiety as Potent Topoisomerase I Inhibitors , 2016, Chemical biology & drug design.

[44]  N. Osheroff,et al.  Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases , 2015, Biochemistry.

[45]  Ding Li,et al.  Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. , 2015, European journal of medicinal chemistry.

[46]  S. K. Mehta,et al.  Surface functionalized selenium nanoparticles for biomedical applications. , 2014, Journal of biomedical nanotechnology.

[47]  R. Nussinov,et al.  The structural basis for cancer treatment decisions , 2014, Oncotarget.

[48]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[49]  H. Watari,et al.  Apoptosis and Molecular Targeting Therapy in Cancer , 2014, BioMed research international.

[50]  M. Rosini,et al.  Polypharmacology: the rise of multitarget drugs over combination therapies. , 2014, Future medicinal chemistry.

[51]  L. Glavaš-Obrovac,et al.  Antineoplastic DNA-Binding Compounds: Intercalating and Minor Groove Binding Drugs , 2013, Arhiv za higijenu rada i toksikologiju.

[52]  Raj Kumar,et al.  Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity. , 2013, Bioorganic & medicinal chemistry.

[53]  L. Ouyang,et al.  Synthesis of novel spirooxindolo-pyrrolidines, pyrrolizidines, and pyrrolothiazoles via a regioselective three-component [3+2] cycloaddition and their preliminary antimicrobial evaluation , 2013, Molecular Diversity.

[54]  H. Chung,et al.  A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. , 2011, European journal of pharmacology.

[55]  F. Da Settimo,et al.  Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. , 2010, Current medicinal chemistry.

[56]  Z. Incesu,et al.  Synthesis of 2-substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2-yl)phenyl]acetamide derivatives and evaluation of their anticancer activity. , 2010, European journal of medicinal chemistry.

[57]  H. Khavasi,et al.  A novel reaction of 6-amino-uracils and isatins , 2008 .

[58]  Iztok Hozo,et al.  Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. , 2008, Archives of internal medicine.

[59]  P. Forterre,et al.  Origin and evolution of DNA topoisomerases. , 2007, Biochimie.

[60]  Alexander Kamb,et al.  Why is cancer drug discovery so difficult? , 2007, Nature Reviews Drug Discovery.

[61]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[62]  J. Schellens,et al.  Dual topoisomerase I/II inhibitors , 2000 .

[63]  M. Lenardo,et al.  Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. , 2000, Journal of cell science.

[64]  S. Kaufmann,et al.  Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  R. Hughes,et al.  Screening of Hepatoprotective Plant Components using a HepG2 Cell Cytotoxicity Assay , 1997, The Journal of pharmacy and pharmacology.

[66]  Y. Aoyagi,et al.  Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II , 1997, Japanese journal of cancer research : Gann.

[67]  J. Riou,et al.  From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. , 1996, European journal of cancer.

[68]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[69]  C. Nguyen,et al.  Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. , 1993, Cancer research.

[70]  Y. Pommier,et al.  Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. , 1993, Molecular pharmacology.

[71]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[72]  W. Gies,et al.  SUPPLEMENT , 1930 .

[73]  A. A. Al-karmalawy,et al.  Cordyline fruticose (L.) A. Chev. Leaves: Isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. , 2021, New Journal of Chemistry.

[74]  V. Ravishankar,et al.  Extracellular Synthesis of Selenium Nanoparticles from an Actinomycetes Streptomyces griseoruber and Evaluation of its Cytotoxicity on HT-29 Cell Line. , 2018, Pharmaceutical nanotechnology.

[75]  V. Adam,et al.  Selenium nanoparticles as a nutritional supplement. , 2017, Nutrition.

[76]  W. Denny,et al.  Dual topoisomerase I/II inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.